
# Children's Mercy KANSAS CITY

## Extracorporeal Membrane Oxygenation (ECMO) Neuromonitoring and Acute Brain Injury Clinical Pathway Synopsis


#### ECMO Neuromonitoring and Acute Brain Injury: Neurological Monitoring Algorithm



Date Finalized: August 2025

2

#### ECMO Neuromonitoring and Acute Brain Injury: Intracranial Hemorrhage on ECMO Algorithm





Date Finalized: August 2025

3

#### ECMO Neuromonitoring and Acute Brain Injury: Post-Neurosurgical Intervention on ECMO Algorithm

#### **Exclusion criteria:** · Ischemic brain injury without hemorrhage Patient on ECMO following neurosurgical Neurosurgical Intervention: intervention · External ventricular drain (EVD) placement Intracranial pressure (ICP) monitor placement Following the procedure, is the Off Pathway Re-establish neuroprotective goals patient stable enough to decannulate? Reassess transfusion thresholds No • Ensure discussion with Neurosurgery occurs before restarting anticoagulation • Start heparin at 10 units/kg/hr then follow heparin goal adjustment per ECMO Bleeding Algorithm • Consider antifibrinolytic infusion as needed for up to 24 hours • Continue ECMO Bleeding Algorithm for up to 24 hours, then slowly relax goals · Assess ECMO circuit for fibrin and clots every hour and as needed • Ensure saline-primed back-up circuit readily available $\circ$ **Attempt** to hold changing of circuit until patient is back on stable anticoagulation (*ECMO circuit or* component change may be needed sooner due to excessive clot) Consider higher ECMO flows to avoid areas of stasis in ECMO circuit and discuss post-op upper limit MAP goals with Neurosurgery to reduce likelihood of rebleeding • Neuromonitoring every hour post-neurosurgical intervention · Re-establish neuroprotective goals with multidisciplinary team · Obtain imaging as clinically indicated Removal of EVD/ICP Monitor

· Remove the device when no longer clinically indicated and in discussion with multidisciplinary team

Intracranial Hemorrhage on ECMO

- $\bullet$  Ensure fibrinogen > 200 mg/dL; platelet count > 120K, PT normal; hPTT 50 70 seconds
- Make a plan for the duration to hold anticoagulation prior to and following device removal
- Consider device removal early in the day to allow for optimal neuromonitoring
   Additionally, consider removing around the time of a circuit change

Date Finalized: August 2025

4

ECMO Neuromonitoring and Acute Brain Injury: Ischemic Injury on ECMO Algorithm

**Under Development** 



Date Finalized: August 2025

#### **Table of Contents**

ECMO Neuromonitoring and Acute Brain Injury: Neurological Monitoring Algorithm	1
ECMO Neuromonitoring and Acute Brain Injury: Intracranial Hemorrhage on ECMO Algorithm	2
ECMO Neuromonitoring and Acute Brain Injury: Post-Neurosurgical Intervention on ECMO Algorithm	3
ECMO Neuromonitoring and Acute Brain Injury: Ischemic Injury on ECMO Algorithm	4
Objective of Clinical Pathway	6
Background	6
Target Users	6
Target Population	6
AGREE II	6
Practice Recommendations	7
Additional Questions Posed by the Clinical Pathway Committee	7
Recommendation Specific for Children's Mercy	7
Measures	7
Value Implications	7
Organizational Barriers and Facilitators	7
Power Plans	7
Clinical Pathway Preparation	8
ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee Members and Representation	8
Clinical Pathway Development Funding	8
Approval Process	8
Review Requested	9
Version History	9
Date for Next Review	9
Implementation & Follow-Up	9
Disclaimer	9
Defendance	4.0



Date Finalized: August 2025

6

#### **Objective of Clinical Pathway**

This clinical pathway standardizes the approach to neuromonitoring in patients at high risk for acute brain injury with the goal of early detection. The ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway will outline special needs and considerations when an intracranial hemorrhage or ischemic brain injury is suspected as the patient is supported on ECMO.

#### **Background**

ECMO supports critically ill patients with cardiopulmonary failure as an advanced lifesaving support technique (Cho et al., 2019; Hanalioglu et al., 2024; Khanduja et al., 2023; Said et al., 2020). Over the past 20 years, the use of ECMO in children has demonstrated a four-fold increase, particularly for those children with severe and refractory cardiac and pulmonary failure (Hanalioglu et al., 2024; Said et al., 2020). While ECMO has life-saving benefits, this support intervention presents a risk of neurological complications, specifically intracranial hemorrhage, ischemic brain injury, cerebral edema, and seizures (Hanalioglu et al., 2024; Khanduja et al., 2023; Pandiyan et al., 2023; Said et al., 2020). Standard neurological monitoring for the early recognition of findings suggestive of a possible acute neurological injury is critical to preventing or limiting the extent of injury (Cho et al., 2019; Pandiyan et al., 2023).

The ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee recognizes that a framework is needed to assist providers in complex decision-making when managing a child on ECMO support and an acute brain injury is detected. The ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway aims to provide this framework by detailing standard neurological monitoring recommendations and the considerations surrounding the care of these patients.

#### **Target Users**

- Physicians (Intensivists [ICN, PICU, CICU], Neurosurgery, Neurology, Hematology, Fellows, Residents)
- Advanced Practice Neonatal/Pediatric Critical Care Nurses
- Nurses (ICN, PICU, CICU)
- ECMO Support Team (ECMO Physician, ECMO Specialist, ECMO Core Team Specialist)

#### Target Population Inclusion Criteria

Patients on ECMO, veno-venous or veno-arterial

#### **AGREE II**

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health national guideline provided guidance to the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee (Pandiyan et al., 2023). See Table 1 for AGREE II.

Table 1

AGREE II Summary for the Clinical Guidelines for Routine Neuromonitoring in Neonatal and Pediatric Patients

Supported on Extracorporeal Membrane Oxygenation (Pandiyan et al., 2023)

Domain	Percent Agreement	Percent Justification^
Scope and purpose	77%	The aim of the guideline, the clinical questions posed, and the target populations <b>were</b> identified.
Stakeholder involvement	26%	The guideline <b>did not</b> include appropriate stakeholders (such as Hematology) nor the viewpoints of the intended user.
Rigor of development	21%	The guideline developers <u>did not</u> provide information on how the evidence was gathered and synthesized, how the recommendations were formulated, or how the guidelines would be updated.
Clarity and presentation	81%	The guideline recommendations <u>are</u> clear, unambiguous, and easily identified; in addition, different management options are presented.



Date Finalized: August 2025

7

Applicability	50%	Barriers and facilitators to implementation and resource implications <u>were</u> <u>addressed</u> in the guideline. The guideline <u>did not</u> address utilization strategies.
Editorial independence	48%	It is <u>unclear</u> if the recommendations were biased by competing interests.
Overall guideline assessment	50%	
See Practice Recomm	nendations	5

Note: Four EBP Scholars completed the AGREE II on this guideline.

#### **Practice Recommendations**

When a neonate or pediatric patient is supported on ECMO, please refer to the National Institute of Neurological Disorders and Stroke clinical guideline (Pandiyan et al., 2023) for neuromonitoring recommendations.

#### **Additional Questions Posed by the Clinical Pathway Committee**

No clinical questions were posed for this review.

#### **Recommendation Specific for Children's Mercy**

Children's Mercy adopted the majority of the practice recommendations made by the National Institute of Neurological Disorders and Stroke Clinical Guideline (Pandiyan et al., 2023). Variations/Additions include:

- Ensuring a consult is placed for inpatient Neuropsychology following ECMO decannulation
- Guidance regarding discharge recommendations for neurodevelopmental follow-up

#### Measures

- Use of the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway
- Process Metrics
  - Rates of electroencephalogram (EEG) monitoring
  - Rates of post-decannulation magnetic resonance imaging
- Outcome Metrics
  - o Rates of brain death/withdrawal of life-sustaining therapy due to brain injury
  - Rates of herniation as surrogates for earlier detection of acute brain injury

#### **Value Implications**

The following improvements may increase value by reducing healthcare costs and non-monetary costs (e.g., missed school/work, loss of wages, stress) for patients and families and reducing costs and resource utilization for healthcare facilities.

- Decreased delay of neuroprotective strategies
- Decreased unwarranted variation in care

#### Organizational Barriers and Facilitators Potential Barriers

- Variability of the acceptable level of risk among providers
- Challenges with follow-up faced by some families

#### **Potential Facilitators**

- Collaborative engagement across care continuum settings during clinical pathway development
- Anticipated high rate of use of the clinical pathway

#### **Power Plans**

- ECMO Cannulation
- ECMO Maintenance

<sup>^</sup> Percentage justification is an interpretation based on the Children's Mercy EBP Department standards.



Date Finalized: August 2025

8

- ECMO Decannulation
- ECMO Bleeding Algorithm
- Extracorporeal Cardiopulmonary Resuscitation
- PICU Post Cardiac Arrest
- CICU Post Cardiac Arrest

#### **Associated Policies**

- ECMO Anticoagulation Guidelines
- Excessive Bleeding in Infant/Child on ECMO Treatment Guidelines

#### **Clinical Pathway Preparation**

This pathway was prepared by the Evidence Based Practice (EBP) Department in collaboration with the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee, composed of content experts at Children's Mercy Kansas City. If a conflict of interest is identified, the conflict will be disclosed next to the committee member's name.

#### ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee Members and Representation

- Jessica Wallisch, MD | Critical Care Medicine | Committee Co-Chair
- Jenna Miller, MD | Critical Care Medicine, Pediatric ECMO Director | Committee Co-Chair
- Asdis Finnsdottir Wagner, DO | Critical Care Medicine | Committee Member
- David Garcia, MD | Neurosurgery | Committee Member
- Christian Kaufman, MD, FAANS | Neurosurgery | Committee Member
- Yong Han, MD | Critical Care Medicine | Committee Member
- John Daniel, MD, MS | Neonatology, Neonatal ECMO Director | Committee Member
- Sara McElroy, MD | Hematology/Oncology/BMT | Committee Member
- Shannon Carpenter, MD, MS | Hematology/Oncology/BMT | Committee Member
- Ara Hall, MD | Neurology | Committee Member
- Marcie Files, MD | Neurology | Committee Member
- Jake Arends, MD | Neurology | Committee Member
- Kari Davidson, MSN, RN, CCRN | Critical Care Nursing, Extracorporeal Support Director | Committee Member
- Debra Newton, RN, MSN, CCRN | Critical Care Nursing, Extracorporeal Support Director | Committee Member
- Natalee Perrin, BSN, RN, CCRN | Critical Care Nursing, Pediatric Intensive Care Unit | Committee Member
- Kristin Wiegert, PharmD, BCPPS | Pharmacy | Committee Member
- Sarah Dierking, MSN, RN, CPHQ | Clinical Practice and Quality | Committee Member

#### **EBP Committee Members**

- Todd Glenski, MD, MSHA, FASA | Anesthesiology, Evidence Based Practice
- Kelli Ott, OTD, OTR/L | Evidence Based Practice

#### Clinical Pathway Development Funding

The development of this clinical pathway was underwritten by the following departments/divisions: Critical Care Medicine, Neurosurgery, Neurology, Neonatology, Hematology/Oncology/BMT, ECMO Program, Pediatric Intensive Care Unit, Pharmacy, Clinical Practice and Quality, and Evidence Based Practice

#### **Conflict of Interest**

The contributors to the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway have no conflicts of interest to disclose related to the subject matter or materials discussed.

#### **Approval Process**

- This pathway was reviewed and approved by the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway Committee, content experts, departments/divisions, and the EBP Department; after which, they were approved by the Medical Executive Committee.
- Pathways are reviewed and updated as necessary every 3 years within the EBP Department at CMKC. Content expert teams are involved with every review and update.



Date Finalized: August 2025

9

**Review Requested** 

Department/Unit	Date Obtained
Critical Care Medicine	July 2025
Neurosurgery	July 2025
Neonatology	July 2025
Neurology	July 2025
Hematology/Oncology/BMT	July 2025
ECMO Program	July 2025
Pharmacy	July 2025
Pediatric Intensive Care Unit	July 2025
Clinical Practice and Quality	July 2025
Evidence Based Practice	June 2025

**Version History** 

Date	Comments			
March 2025	Version one – (Neurological Monitoring algorithm developed; associated powerplans			
	reviewed and updated)			
August 2025	Version two – (Neurological Monitoring algorithm revised; Intracranial Hemorrhage o			
	ECMO and Post-Neurosurgical Intervention on ECMO algorithms developed; associated			
	powerplans reviewed; synopsis developed)			
November 2025	Version three – (Neurological Monitoring algorithm revised to further clarify guidance			
	for EEG monitoring)			
Under	Version four – (Neurological Monitoring algorithm revised; Ischemic Brain Injury on			
development	ECMO algorithm developed; associated powerplans reviewed; synopsis revised)			

#### **Date for Next Review**

August 2028

#### **Implementation & Follow-Up**

- Once approved, the pathway was presented to appropriate care teams and implemented. Care measurements will be assessed and shared with appropriate care teams to determine if changes need to occur.
- Order sets/power plans consistent with recommendations were reviewed, and updates were requested.
- Education was provided to all stakeholders:

Nursing units where the ECMO Neuromonitoring and Acute Brain Injury Clinical Pathway is used Departments of Neurology, Neurosurgery, and Hematology

Providers from ICN, PICU, and CICU

Resident physicians

Additional institution-wide announcements were made via email, the hospital website, and relevant huddles.

#### Disclaimer

When evidence is lacking or inconclusive, options in care are provided in the supporting documents and the power plan(s) that accompany the clinical pathway.

These clinical pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment to determine what is in the best interests of the patient based on the circumstances existing at the time.

It is impossible to anticipate all possible situations that may exist and to prepare clinical pathways for each. Accordingly, these clinical pathways should guide care with the understanding that departures from them may be required at times.

Date Finalized: August 2025

#### References

- Anselmi, A., Guinet, P., Ruggieri, V. G.., Aymami, M., Lelong, B., Granry, S., Malledant, Y., Le Tulzo, Y., Gueret, P., Verhoye, J. P., & Flecher, E. (2016). Safety of recombinant factor VIIa in patients under extracorporeal membrane in oxygenation. *European Journal of Cardio-Thoracic Surgery*, 49(1), 78-84. https://doi.org/10.1093/ejcts/ezv140
- Callier, K., Dantes, G., Johnson, K., & Linden, A. F. (2023). Pediatric ECLS neurologic management and outcomes. Seminars in Pediatric Surgery, 32(4), 151331. https://doi.org/10.1016/j.sempedsurg.2023.151331
- Cho, S. M., Hwang, J., Chiarini, G., Amer, M., Antonini, M. V., Barrett, N., Belohlavek, J., Brodie, D., Dalton, H. J., Diaz, R., Elhazmi, A., Tahsili-Fahadan, P., Fanning, J., Fraser, J., Hoskote, A., Jung, J. S., Lotz, C., MacLaren, G., Peek, G., Polito, A., ...Lorusso, R. (2024). Neurological monitoring and management for adult extracorporeal membrane oxygenation patients: Extracorporeal Life Support Organization consensus guidelines. *Critical Care* (London, England), 28(1), 296. https://doi.org/10.1186/s13054-024-05082-z
- Clair, M. P., Rambaud, J., Flahault, A., Guedj, R., Guilbert, J., Guellec, I., Durandy, A., Demoulin, M., Jean, S., Mitanchez, D., Chalard, F., Sileo, C., Carbajal, R., Renolleau, S., & Léger, P. L. (2017). Prognostic value of cerebral tissue oxygen saturation during neonatal extracorporeal membrane oxygenation. *Public Library of Science* (*PLoS*) *One*, *12*(3), e0172991. <a href="https://doi.org/10.1371/journal.pone.0172991">https://doi.org/10.1371/journal.pone.0172991</a>
- Hanalioglu, D., Temkit, M., Hildebrandt, K., MackDiaz, E., Goldstein, Z., Aggarwal, S., & Appavu, B. (2024). Neurophysiologic features reflecting brain injury during pediatric ECMO support. *Neurocritical Care*, 40(2), 759-768. https://doi.org/10.1007/s12028-023-01836-9
- Intracranial Hemorrhage on Extracorporeal Support Guideline (October, 2018), CMH Patient Care Manual. Children's Mercy Hospital, Kansas City, Missouri
- Khanduja, S., Kim, J., Kang, J. K., Feng, C. Y., Vogelsong, M. A., Geocadin, R. G., Whitman, G., & Cho, S. M. (2023). Hypoxic-Ischemic brain injury in ECMO: Pathophysiology, neuromonitoring, and therapeutic opportunities. *Cells*, 12(11), 1546. <a href="https://doi.org/10.3390/cells12111546">https://doi.org/10.3390/cells12111546</a>
- Laws, J. C., Jordan, L. C., Pagano, L. M., Wellons, J. C., & Wolf, M. S. (2022). Multimodal neurologic monitoring in children with acute brain injury. *Pediatric Neurology*, *129*, 62-71. https://doi.org/10.1016/j.pediatrneurol.2022.01.006
- Lee, S., Ryan, K. R., Murray, J., Chen, S., Grant, G. A., Wilkins, S., Yarlagadda, V. V., Wintermark, M., Dodd, R., Rosenthal, D., Teuteburg, J., Navaratnam, M., Lee, J., Jordan, L. C., & Almond, C. S. (2023). Multidisciplinary stroke pathway for children supported with ventricular assist devices. *ASAIO Journal (American Society for Artificial Internal Organs: 1992)*, 69(4), 402-410. https://doi.org/10.1097/MAT.000000000001822
- Mullenbach, R. M., Kredel, M., Kunze, E., Kranke, P., Kuestermann, J., Brack, A., Gorski, A., Wunder, C., Roewer, N., & Wurmb, T. (2012). Prolonged heparin-free extracorporeal membrane oxygenation in multiple injured acute respiratory distress syndrome patients with traumatic brain injury. *Journal of Trauma and Acute Care Surgery*, 72(5), 1444-1447. <a href="https://dooi.org/10.1097/TA.0b013e31824d68e3">https://dooi.org/10.1097/TA.0b013e31824d68e3</a>
- Pandiyan, P., Cvetkovic, M., Antonini, M. V., Shappley, R. K. H., Karmakar, S. A., & Raman, L. (2023). Clinical guidelines for routine neuromonitoring in neonatal and pediatric patients supported on extracorporeal membrane oxygenation. *American Society for Artificial Internal Organs Journal*, 69(10), 895-900. https://doi.org/10.1097/MAT.000000000001896
- Prokupets, R., Kannapadi, N., Chang, H., Caturegli, G., Bush, E. L., Kim, B. S., Keller, S., Geocadin, R. G., Whitman, G. J. R., Cho, S. M., & HERALD Investigators. (2023). Management of anticoagulation therapy in ECMO-Associated ischemic stroke and intracranial hemorrhage. *Innovations (Philadelphia, PA)*, 18(1), 49-57. <a href="https://doi.org/10.1177/1556984522114170">https://doi.org/10.1177/1556984522114170</a>
- Said, A. S., Guilliams, K. P., & Bembea, M. M. (2020). Neurological monitoring and complications of pediatric extracorporeal membrane oxygenation support. Pediatric Neurology, 108, 31-39. https://doi.org/10.1016/j.pediatrneurol.2020.03.014
- Themas, K., Zisis, M., Kourek, C., Konstantinou, G., D'Anna, L., Papanagiotou, P., Ntaios, G., Dimopoulos, S., & Korompoki, E. (2024). Acute ischemic stroke during extracorporeal membrane oxygenation (ECMO): A narrative review of the literature. Journal of Clinical Medicine, 13(19), 6014. https://doi.org/10.3390/jcm13196014



Date Finalized: August 2025

11

Waraich, M., & Ajayan, N. (2023). Clinical neuroprotection and secondary neuronal injury mechanisms. *Anaesthesia and Intensive Care Medicine*, 25(1), 16-22. https://doi.org/10.1016/j.mpaic.2023.11.009